A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

PHASE2TerminatedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 8, 2021

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions
Covid19Hypoxemia
Interventions
DRUG

Ambrisentan

Endothelin receptor antagonist

DRUG

Placebo

Placebo

Trial Locations (13)

10000

University Hospital for Infectious Diseases Fran Mihaljevic, Zagreb

18014

Hospital Universitario Virgen de las Nieves, Granada

18016

Hospital Universitario San Cecilio, Granada

23000

General Hopital Zadar, Zadar

23007

Hospital Universitario de Jaén, Jaén

28031

Hospital Universitario Infanta Leonor, Madrid

28041

University Hospital 12 de Octubre, Madrid

28046

Hospital Universitario La Paz, Madrid

28055

Hospital de Emergencias Enfermera Isabel Zendal, Madrid

28933

Hospital Rey Juan Carlos, Móstoles

31008

Complejo Hospitalario de Navarra, Pamplona

33394

Hospital Universitario de Cabueñes, Gijón

48960

Hospital Universitario de Galdakao-Usansolo, Galdakao

Sponsors
All Listed Sponsors
lead

Noorik Biopharmaceuticals AG

INDUSTRY